A randomized, open-label study of the safety and tolerability of PEGASYS plus ribavirin in patients with chronic hepatitis C viral infection, genotype-1, and HIV-1 co-infection receiving, or discontinuing, highly active antiretroviral therapy (HAART).
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2010
At a glance
- Drugs Antiretrovirals; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C; HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 23 Jun 2006 New trial record.